ArticleAnnals of neurology2022
Plasma MIA, CRP, and Albumin Predict Cognitive Decline in Parkinson's Disease.
Article in Annals of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Machine learning methods for the detection and prediction of cognitive impairment in Parkinson's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2025Pooled it
- Frailty in Parkinson's disease: time to integrate it into treatment decision-making?Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Characteristics and mechanisms of cognitive impairment in Parkinson disease.Nature reviews. Neurology · 2026Review
- Machine learning-based non-invasive Parkinson's disease diagnostic model using clinical blood biomarkers.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease.Annals of clinical and translational neurology · 2025Article
- Associations of digestive diseases exposure and lifestyle factors with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- The Red Blood Cell Distribution Width-to-Albumin Ratio's Role in Parkinson's Disease: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Parkinson's disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction.NPJ Parkinson's disease · 2025Article
- A Multi-omics Framework Based on Machine Learning as a Predictor of Cognitive Impairment Progression in Early Parkinson's Disease.Neurology and therapy · 2025Article
- Red blood cell distribution width to albumin ratio (RAR) is associated with low cognitive performance in American older adults: NHANES 2011-2014.BMC geriatrics · 2025Article
- Associations of frailty and cognitive impairment with all-cause and cardiovascular mortality in older adults: a prospective cohort study from NHANES 2011-2014.BMC geriatrics · 2025Article
- Plasma fibronectin is a prognostic biomarker of disability in Parkinson's disease: a prospective, multicenter cohort study.NPJ Parkinson's disease · 2025Article
- Interpretable machine learning for cognitive impairment prediction in Parkinson's disease: a multicenter validation study with SHAP analysis.Frontiers in aging neuroscience · 2025Article
- Machine Learning for Early Detection of Cognitive Decline in Parkinson's Disease Using Multimodal Biomarker and Clinical Data.Biomedicines · 2024Article
- Association between geriatric nutritional risk index and cognitive function in older adults with/without chronic kidney disease.Brain and behavior · 2024Article
- Serum albumin and white matter hyperintensities.Translational psychiatry · 2024Article
- Adipokines, Vitamin D, and Selected Inflammatory Biomarkers among Parkinson's Disease Patients with and without Dyskinesia: A Preliminary Examination.Metabolites · 2024Article
- Serum albumin and white matter hyperintensities.Research square · 2024Article
- An interpretable multiparametric radiomics model of basal ganglia to predict dementia conversion in Parkinson's disease.NPJ Parkinson's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveUsing a multi-cohort, discovery-replication-validation design, we sought new plasma biomarkers that predict which individuals with Parkinson's disease (PD) will experience cognitive decline.
methodsIn 108 discovery cohort PD individuals and 83 replication cohort PD individuals, we measured 940 plasma proteins on an aptamer-based platform. Using proteins associated with subsequent cognitive decline in both cohorts, we trained a logistic regression model to predict which patients with PD showed fast (> = 1 point drop/year on Montreal Cognitive Assessment [MoCA]) versus slow (< 1 point drop/year on MoCA) cognitive decline in the discovery cohort, testing it in the replication cohort. We developed alternate assays for the top 3 proteins and confirmed their ability to predict cognitive decline - defined by change in MoCA or development of incident mild cognitive impairment (MCI) or dementia - in a validation cohort of 118 individuals with PD. We investigated the top plasma biomarker for causal influence by Mendelian randomization (MR).
resultsA model with only 3 proteins (melanoma inhibitory activity protein [MIA], C-reactive protein [CRP], and albumin) separated fast versus slow cognitive decline subgroups with an area under the curve (AUC) of 0.80 in the validation cohort. The individuals with PD in the validation cohort in the top quartile of risk for cognitive decline based on this model were 4.4 times more likely to develop incident MCI or dementia than those in the lowest quartile. Genotypes at MIA single nucleotide polymorphism (SNP) rs2233154 associated with MIA levels and cognitive decline, providing evidence for MIA's causal influence.
conclusionsAn easily obtained plasma-based predictor identifies individuals with PD at risk for cognitive decline. MIA may participate causally in development of cognitive decline. ANN NEUROL 2022;92:255-269.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.